BACKGROUND: Cystic fibrosis (CF) is characterized by recurrent respiratory infections and progressive lung disease. Although environmental factors account for 50% of the variation in CF lung function, few specific exposures have been identified. Studies using small study samples focusing on environmental allergies in CF have had inconsistent results. Our objective was to examine the role of environmental allergies in upper and lower respiratory tract morbidities in CF. METHODS: A total of 1,321 subjects with CF were recruited through the U.S. CF Twin-Sibling Study. Questionnaires were used to determine the presence/absence of environmental allergies. Questionnaires, chart review, and U.S. CF Foundation Patient Registry data were used to track outcomes. RESULTS: Within the study sample 14% reported environmental allergies. Environmental allergies were associated with a higher risk of sinus disease (adjusted OR: 2.68; P < 0.001) and nasal polyps (adjusted OR: 1.74; P = 0.003). Environmental allergies were also associated with a more rapid decline in lung function (additional -1.1%/year; P = 0.001). However, allergies were associated with a later median age of acquisition of Pseudomonas aeruginosa (6.6 years vs. 4.4 years; log rank P = 0.027). The reported use of common allergy medications, anti-histamines and leukotriene inhibitors, did not alter the frequency of respiratory morbidities. CONCLUSIONS: Environmental allergies are associated with an increased risk of sinus disease and nasal polyps and a more rapid decline in CF lung function, but may have a protective effect against the acquisition of P. aeruginosa. Prospective studies are needed to confirm these associations which have implications for more aggressive management of allergies.
BACKGROUND:Cystic fibrosis (CF) is characterized by recurrent respiratory infections and progressive lung disease. Although environmental factors account for 50% of the variation in CF lung function, few specific exposures have been identified. Studies using small study samples focusing on environmental allergies in CF have had inconsistent results. Our objective was to examine the role of environmental allergies in upper and lower respiratory tract morbidities in CF. METHODS: A total of 1,321 subjects with CF were recruited through the U.S. CF Twin-Sibling Study. Questionnaires were used to determine the presence/absence of environmental allergies. Questionnaires, chart review, and U.S. CF Foundation Patient Registry data were used to track outcomes. RESULTS: Within the study sample 14% reported environmental allergies. Environmental allergies were associated with a higher risk of sinus disease (adjusted OR: 2.68; P < 0.001) and nasal polyps (adjusted OR: 1.74; P = 0.003). Environmental allergies were also associated with a more rapid decline in lung function (additional -1.1%/year; P = 0.001). However, allergies were associated with a later median age of acquisition of Pseudomonas aeruginosa (6.6 years vs. 4.4 years; log rank P = 0.027). The reported use of common allergy medications, anti-histamines and leukotriene inhibitors, did not alter the frequency of respiratory morbidities. CONCLUSIONS: Environmental allergies are associated with an increased risk of sinus disease and nasal polyps and a more rapid decline in CF lung function, but may have a protective effect against the acquisition of P. aeruginosa. Prospective studies are needed to confirm these associations which have implications for more aggressive management of allergies.
Authors: J Michael Collaco; Scott M Blackman; John McGready; Kathleen M Naughton; Garry R Cutting Journal: J Pediatr Date: 2010-06-30 Impact factor: 4.406
Authors: Xin-jie Zhu; Lu-ping Zhu; Mei-ping Lu; Mei-lin Wang; Qin-hong Qi; Min Yin; Zheng-dong Zhang; Lei Cheng Journal: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi Date: 2010-06
Authors: M N Feuillet-Fieux; G Lenoir; I Sermet; C Elie; J Djadi-Prat; M Ferrec; M Magen; V Couloigner; Y Manach; B Lacour; J P Bonnefont Journal: Rhinology Date: 2011-08 Impact factor: 3.681
Authors: Deanna M Green; Kathryn E McDougal; Scott M Blackman; Patrick R Sosnay; Lindsay B Henderson; Kathleen M Naughton; J Michael Collaco; Garry R Cutting Journal: Respir Res Date: 2010-10-08
Authors: Joseph M Collaco; John McGready; Deanna M Green; Kathleen M Naughton; Christopher P Watson; Timothy Shields; Scott C Bell; Claire E Wainwright; Garry R Cutting Journal: PLoS One Date: 2011-11-18 Impact factor: 3.240
Authors: Christopher B Morrow; Karen S Raraigh; Deanna M Green; Scott M Blackman; Garry R Cutting; Joseph M Collaco Journal: J Pediatr Date: 2014-07-12 Impact factor: 4.406
Authors: Weili Li; David Soave; Melissa R Miller; Katherine Keenan; Fan Lin; Jiafen Gong; Theodore Chiang; Anne L Stephenson; Peter Durie; Johanna Rommens; Lei Sun; Lisa J Strug Journal: Hum Genet Date: 2013-09-22 Impact factor: 4.132
Authors: Steven Conway; Ian M Balfour-Lynn; Karleen De Rijcke; Pavel Drevinek; Juliet Foweraker; Trudy Havermans; Harry Heijerman; Louise Lannefors; Anders Lindblad; Milan Macek; Sue Madge; Maeve Moran; Lisa Morrison; Alison Morton; Jacquelien Noordhoek; Dorota Sands; Anneke Vertommen; Daniel Peckham Journal: J Cyst Fibros Date: 2014-05 Impact factor: 5.482
Authors: Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco Journal: Expert Rev Respir Med Date: 2020-04-26 Impact factor: 3.772